Glimepirid Mylan (Glimepiride)

Glimepirid Mylan is indicated for the oral management of hyperglycemia in patients with type 2 diabetes mellitus, typically when diet, exercise, and other oral agents are insufficient.

• As monotherapy in adults with type 2 diabetes when lifestyle changes alone do not achieve glycemic targets.
• In combination with metformin to improve glycemic control.
• As part of a multi‑drug regimen that may include other oral antidiabetics such as DPP‑4 inhibitors.
• For patients who require a once‑daily sulfonylurea to simplify dosing.
• To assist in achieving HbA1c reductions as recommended by clinical guidelines.

Side effects reported with glimepiride vary in frequency and severity.

Common

• Low blood sugar (hypoglycemia) especially if meals are missed.
• Weight gain.
• Nausea or abdominal discomfort.
• Headache.

Serious

• Severe hypoglycemia requiring assistance.
• Allergic reactions such as rash, itching, or swelling.
• Liver enzyme elevations.
• Blood cell disorders (e.g., leukopenia, thrombocytopenia).

Before starting Glimepirid Mylan, healthcare providers should evaluate several safety considerations.

• Assess renal and hepatic function, as impairment may affect drug clearance.
• Review history of hypoglycemia or adrenal insufficiency.
• Use cautiously in elderly patients due to increased hypoglycemia risk.
• Avoid use during pregnancy or breastfeeding unless benefits outweigh risks.
• Monitor blood glucose regularly to adjust therapy.
• Consider cardiovascular status, as sulfonylureas may influence heart disease risk.

Glimepirid Mylan can interact with other medicines, altering its effectiveness or safety profile.

Avoid

• Concurrent use with other sulfonylureas or insulin, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma levels.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can raise blood glucose.
• Certain antibiotics (e.g., quinolones) that may affect glucose control.
• NSAIDs, which can potentiate hypoglycemic effects.